PD-L1 in melanoma: facts and myths

The use of monoclonal antibodies that block immunologic checkpoints that would otherwise mediate the adaptive immune resistance have paved the way in cancer treatment. There is evidence that blocking the PD-1/PD-L1 axis is a strategy of overriding importance in the treatment of patients with metasta...

Full description

Saved in:
Bibliographic Details
Published in:Melanoma Manag
Main Authors: Mandalà, Mario, Merelli, Barbara, Massi, Daniela
Format: Artigo
Language:Inglês
Published: Future Medicine Ltd 2016
Subjects:
Perspective
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC6096437/
https://ncbi.nlm.nih.gov/pubmed/30190888
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/mmt-2016-0013
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items